235 related articles for article (PubMed ID: 24604117)
1. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.
Liu G; Sun Y; Ji P; Li X; Cogdell D; Yang D; Parker Kerrigan BC; Shmulevich I; Chen K; Sood AK; Xue F; Zhang W
J Pathol; 2014 Jul; 233(3):308-18. PubMed ID: 24604117
[TBL] [Abstract][Full Text] [Related]
2. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.
Anders L; Ke N; Hydbring P; Choi YJ; Widlund HR; Chick JM; Zhai H; Vidal M; Gygi SP; Braun P; Sicinski P
Cancer Cell; 2011 Nov; 20(5):620-34. PubMed ID: 22094256
[TBL] [Abstract][Full Text] [Related]
3. miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop.
Deng M; Zeng C; Lu X; He X; Zhang R; Qiu Q; Zheng G; Jia X; Liu H; He Z
Cancer Lett; 2017 Sep; 403():175-185. PubMed ID: 28634044
[TBL] [Abstract][Full Text] [Related]
4. MiR-498 regulated FOXO3 expression and inhibited the proliferation of human ovarian cancer cells.
Liu R; Liu F; Li L; Sun M; Chen K
Biomed Pharmacother; 2015 May; 72():52-7. PubMed ID: 26054675
[TBL] [Abstract][Full Text] [Related]
5. Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.
Rodgers LH; Ó hAinmhire E; Young AN; Burdette JE
Oncotarget; 2016 May; 7(22):32785-95. PubMed ID: 27129161
[TBL] [Abstract][Full Text] [Related]
6. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
Wang Y; Qiu C; Lu N; Liu Z; Jin C; Sun C; Bu H; Yu H; Dongol S; Kong B
Int J Oncol; 2018 Jun; 52(6):2130-2142. PubMed ID: 29620165
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G
Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362
[TBL] [Abstract][Full Text] [Related]
8. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
Xia B; Yang S; Liu T; Lou G
Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
[TBL] [Abstract][Full Text] [Related]
9. Co-regulation and function of
Barger CJ; Chee L; Albahrani M; Munoz-Trujillo C; Boghean L; Branick C; Odunsi K; Drapkin R; Zou L; Karpf AR
Elife; 2021 Apr; 10():. PubMed ID: 33890574
[TBL] [Abstract][Full Text] [Related]
10. The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer.
Liu C; Huang Y; Cui Y; Zhou J; Qin X; Zhang L; Li X; Li Y; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Hu D; Xiao R; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Qin T; You L; Lu F; Sun C
Front Immunol; 2021; 12():799171. PubMed ID: 35095879
[TBL] [Abstract][Full Text] [Related]
11. miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression.
Jiang S; Zhao C; Yang X; Li X; Pan Q; Huang H; Wen X; Shan H; Li Q; Du Y; Zhao Y
Int J Mol Med; 2016 Jul; 38(1):113-22. PubMed ID: 27247259
[TBL] [Abstract][Full Text] [Related]
12. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.
Rader J; Russell MR; Hart LS; Nakazawa MS; Belcastro LT; Martinez D; Li Y; Carpenter EL; Attiyeh EF; Diskin SJ; Kim S; Parasuraman S; Caponigro G; Schnepp RW; Wood AC; Pawel B; Cole KA; Maris JM
Clin Cancer Res; 2013 Nov; 19(22):6173-82. PubMed ID: 24045179
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
14. [Role of miR-206/CDK4 in modulating the growth and chemotlerapy sensitivity of ovarian cancer cells].
Ling C; Liu S; Wang Y; Zhang FC; DU Y
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Mar; 37(3):393-397. PubMed ID: 28377359
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1.
Vishnubalaji R; Hamam R; Yue S; Al-Obeed O; Kassem M; Liu FF; Aldahmash A; Alajez NM
Oncotarget; 2016 Jun; 7(24):35789-35802. PubMed ID: 27119506
[TBL] [Abstract][Full Text] [Related]
16. miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma.
Arts FA; Keogh L; Smyth P; O'Toole S; Ta R; Gleeson N; O'Leary JJ; Flavin R; Sheils O
Hum Pathol; 2017 Dec; 70():98-104. PubMed ID: 29079174
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1.
Liu X; Xie T; Mao X; Xue L; Chu X; Chen L
Cell Physiol Biochem; 2016; 39(2):617-29. PubMed ID: 27415661
[TBL] [Abstract][Full Text] [Related]
18. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
20. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.
Lok GT; Chan DW; Liu VW; Hui WW; Leung TH; Yao KM; Ngan HY
PLoS One; 2011; 6(8):e23790. PubMed ID: 21858223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
